Chopra Hriday Kumar, Sethi Kamal Kumar, Nair Tiny, Ponde Chandrashekhar, Ray Saumitra, Rao Sarita, Sundaram Shanmunga, Khullar Dinesh, Nanda Navin C, Sawhney Jatinder Pal Singh, Bajaj Sarita, Mehta Yatin, Pancholia Ashok Kumar, Jain Pradeep, Omar Ashok Kumar, Kapoor Aditya, Sethi Rishi, Abhyankar Atul, Sharma Vinod, Dhall Anil, Sinha Ajay, Mishra Shishu Shankar, Rautray Satya Narayan, Sharma Gyarsi Lal, Mehta Ashwani, Agarwala Rajeev, Rajput Rajeev, Mahajan Ajay, Porwal Sanjay, Hotchandani Ramesh, Rastogi Vishal, Passey Rajiv, Bhargava Mohan, Paul Gnanaraj Justin, Prabhakaran Dorairaj, Singh Vivudh P, Mittal Vinod, Gupta Vitull, Bhalla Anil Kumar, Katyal Virender Kumar, Vijaylakshami Ishwarappa Balekundri, Moorthy Asha, Malhotra Poonam, Arora Vanita, Bhatia Mona, Bhat Prabhavathy, Chhabra Shibba T, Gopal Sugandhi, Deb Tripti, Gupta Preeti, Tewari Hemlata, Goel Anupam, Mishra Rekha, Singh Lovelina, Khan Zakia, Sheth Geeta, Mukhi Chandra, Kalra Inder Pal Singh, Arora Yogender Kumar, Das Uttara, Tyagi Kavita, Pathak Satya Nand, Kubba Samir, Bagga Saurabh, Mahilmaran Asha, Sattur Ameet, Tandon Rohit, Jain Dharmender, Shah Hetan, Majella Cecily, Prakash Ravi, Aggarwal Manish, Verma Ruchi, Sethi Sumit, Gujral Alka, Sood Kanika, Rawat Sonia, Kaul Varsha, Arora Surinder S, Arora Manjiti, Bhat Veena, Bali Anil Kumar, Sood Sanjay, Dawesar Shakuntala, Dawesar Bhushan K, Deka Nilakshi, Paithankar Makarand, Handa Rajiv, Parmar Nitish, Nabi Sheikh U, Garg Naveen, Sharma Sandeep, Tandon Vivek, Pabrai Manoj, Alam Samshad, Tyagi Manju, Sahay Manisha, Hotchandani Manju, Kathpalia Anupama, Kathpalia Ish, Chaudhary Sangeeta, Kukreja Kiran, Agrawal Vikas, Khan Inam D, Garg Prachi, Naryana Satya, Mangla Pawan Kumar, Mehrotra Rajiv, Garg Rajiv, Satyanarayan Upadhyayula, Malhotra Himani, Kumar Kapil, Raj Lokesh, Kalyani Shachi, Garg Vijay, Khan Ali H, Singh Harman P, Gupta Sajal, Singh T C, Rastogi Vipul, Ramteke Rahul, Bhalla Sukriti, Sanguri Ritesh, Niranjan Sumit K, Singla Rohit, Kumar Alok, Grover Anu
Senior Consultant, Department of Cardiology, Moolchand Hospital, Delhi, Delhi, India.
Chairman and Managing Director, Department of Cardiology, Delhi Heart and Lung Institute, New Delhi, Delhi.
J Assoc Physicians India. 2025 May;73(5):e16-e33. doi: 10.59556/japi.73.0957.
Cardiovascular diseases (CVDs) represent a significant health concern worldwide, with women facing distinct challenges in the prevention, diagnosis, and management of these conditions. In India, hypertension is a prevalent cardiovascular (CV) risk factor, affecting nearly one-third of adults, and women experience a disproportionately high burden across all age-groups. The CV continuum, which spans from risk factors to CV events and ultimately to heart failure (HF), demonstrates how the progression of CVD impacts women at each stage differently due to gender-specific mechanisms like hormonal influences, pregnancy complications and the effects of menopause. This manuscript aims to present a set of consensus statements developed by an expert panel in India, focusing on the role of bisoprolol across the CV continuum with special attention to women. The consensus was formed based on a thorough review of clinical experiences, existing clinical data and alignment with both global and regional clinical guidelines. The manuscript highlights the gender-specific CV risks faced by women, their higher mortality rates following acute cardiac events, delayed diagnoses and less aggressive treatments. It also discusses bisoprolol as an effective therapy for managing hypertension, HF and other CV conditions in women. Bisoprolol's benefits include consistent blood pressure (BP) control, improved outcomes in HF and reduced CV risks, particularly in postmenopausal women and those with comorbidities. The manuscript underscores the need for gender-tailored approaches to the CV continuum, from prevention through to management, to address these challenges and improve outcomes for women.
心血管疾病（CVDs）是全球重大的健康问题，女性在这些疾病的预防、诊断和管理上面临着独特的挑战。在印度，高血压是一种普遍的心血管（CV）风险因素，影响着近三分之一的成年人，而且在所有年龄组中，女性承受的负担都过高。心血管连续体，从风险因素到心血管事件，最终到心力衰竭（HF），展示了心血管疾病的进展如何由于激素影响、妊娠并发症和更年期影响等性别特异性机制，在每个阶段对女性产生不同的影响。本手稿旨在呈现印度一个专家小组制定的一系列共识声明，重点关注比索洛尔在心血管连续体中的作用，特别关注女性。该共识是在对临床经验、现有临床数据进行全面审查并与全球和地区临床指南保持一致的基础上形成的。手稿强调了女性面临的性别特异性心血管风险、急性心脏事件后的较高死亡率、诊断延迟和治疗不够积极的情况。它还讨论了比索洛尔作为治疗女性高血压、心力衰竭和其他心血管疾病的有效疗法。比索洛尔的益处包括持续控制血压（BP）、改善心力衰竭的预后以及降低心血管风险，特别是在绝经后女性和患有合并症的女性中。手稿强调了在心血管连续体中从预防到管理都需要采用针对性别的方法，以应对这些挑战并改善女性的预后情况。
